Figure 2 from Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Year: 2025
Type: other
Abstract: Pharmacodynamic analysis of STING signature and cytokine production in patients treated with dazostinag and pembrolizumab following radiation. A, STING signature score fold change by dazostinag doses and normalized to cycle 1, 0 hours. Median fold change across 32 patients per dose per time point plotted. B–H, IL6, IFNγ, IP-10, MCP-1, MIP-1α, MIP-1β, and eotaxin-3 cytokines concentration in plasma samples from 21 patients at screening (before radiation) and at 0 and 6 hours after dazostinag administration. Data are shown as the mean fold change (±SEM) normalized to cycle one, 0-hour levels in patients treated with indicated doses of dazostinag and pembrolizumab. CXCL-10, CXC ligand 10.
Authors: Benjamin T. Cooper, Wade T. Iams, David B. Page, Yuan Yuan, Naamit K. Gerber, Jason J. Luke, John P. Gibbs, Richard C. Gregory, Kwok-Kin Wong, Jiehui Deng, Samanthi A. Perera, Kai Ding, Emily R. Roberts, Allison Berger, Camilla L. Christensen, Erica Xin Tong, Angel E. Maldonado López, Vicky A. Appleman, E. Jane Leonard, Alexander Parent, Yu-Chung Huang, Camden Bay, Cong Li, Neil Lineberry, Jeffrey Raizer, Daniel J. Olson, Steven J. Chmura
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7117698889